Stay updated on Eplontersen in ATTR CM: Clinical Trial
Sign up to get notified when there's something new on the Eplontersen in ATTR CM: Clinical Trial page.

Latest updates to the Eplontersen in ATTR CM: Clinical Trial page
- Check2 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.9%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated to version v2.16.2, and the previous version's helpful links provided by Ionis Pharmaceuticals, Inc. for the CARDIO-TTRansform website have been removed.SummaryDifference0.3%
- Check38 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check66 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check81 days agoChange DetectedThe page has been updated to include new information about Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) and the EudraCT number for ION-682884-CS2, while significant details regarding the study's design and inclusion/exclusion criteria have been removed.SummaryDifference14%
Stay in the know with updates to Eplontersen in ATTR CM: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Eplontersen in ATTR CM: Clinical Trial page.